Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.45M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.09M
Average 0.22M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Nyxoah S.A.
NASDAQ:NYXH
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +48.1% | +93.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +48.1% over three years. Forward estimates point to Revenue at +93.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
OmniAb, Inc. NASDAQ:OABI | $716.17M | $4.91 | Not rated | -5.2 | +201.20% |
Prenetics Global Limited NASDAQ:PRE | $279.64M | $16.51 | Undervalued | -4.9 | -19.95% |
OraSure Technologies, Inc. NASDAQ:OSUR | $249.95M | $3.62 | Not rated | -4.0 | +71.09% |
Utah Medical Products, Inc. NASDAQ:UTMD | $205.05M | $71.97 | Undervalued | 19.6 | +33.89% |
Invivyd, Inc. NASDAQ:IVVD | $171.58M | $0.58 | Not rated | -3.9 | -81.42% |
KORU Medical Systems, Inc. NASDAQ:KRMD | $160.49M | $3.70 | Overvalued | -80.2 | -21.82% |
Protara Therapeutics, Inc. NASDAQ:TARA | $155.77M | $2.53 | Not rated | -2.7 | -62.73% |
Perspective Therapeutics, Inc. AMEX:CATX | $113.89M | $0.94 | Not rated | -0.0 | -63.02% |
Neuronetics, Inc. NASDAQ:STIM | $108.04M | $1.39 | Not rated | -2.3 | -4.62% |
Continue the stock analysis
Jump to another research area for this company.